In vitro and in silico PTP-1B inhibition and in vivo antidiabetic activity of semisynthetic moronic acid derivatives

详细信息    查看全文

• 作者：Litzia Ceró ; n-Romero^a ; Paolo Paoli^b ; Guido Camici^b ; Virginia Flores-Morales^c ; Marí ; a Yolanda Rios^d ; Juan J. Ramí ; rez-Espinosa^a ; Sergio Hidalgo-Figueroa^a ; Gabriel Navarrete-Vá ; zquez^a ; Samuel Estrada-Soto^a ; ^{enoch@uaem.mx" class="auth_mail" title="E-mail the corresponding author}
• 关键词：RGKMKULXFZOUPF-BQSMYOSZSA-N ; SXYLITRDEAEYTJ-MGPMMZCJSA-N
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：15 April 2016
• 年：2016
• 卷：26
• 期：8
• 页码：2018-2022
• 全文大小：1434 K

文摘

Six derivatives (1–6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed. Derivatives 2 (IC₅₀ = 10.8 ± 0.5 μM) and 6 (IC₅₀ = 7.5 ± 0.1 μM) displayed the most potent inhibitory activity. Therefore, they (50 mg/Kg) were tested for their antidiabetic effect in vivo using a non-insulin dependent diabetes mellitus rat model. The results indicated that they decrease plasma glucose levels during all the experiment (p <0.05). Docking analysis of 2 and 6 with PTP-1B orthosteric site A and allosteric site B, showed that 2 had polar and Van der Waals interactions in both sites with Val49, Gln262, Met258, Phe182, Ala217, Ile219 and Gly259, displaying more affinity for site A. Compound 6 showed polar interaction with Gln262 and Van der Waals with Val49, Ile219, Gly259, Arg254, Ala27, Phe52, Met258, Asp48 and Phe182, suggesting that the potential binding site is localized in site B, close to the catalytic site A. Therefore, derivatives 2 and 6 have potential for the development of antidiabetic agents.